All In Biotech

Drug Trial Radar · NCT07277582

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

A Phase 2/3, Two-part, Dose-ranging, Adaptive Study to Evaluate Efficacy and Safety of THRV-1268 in Participants Diagnosed With Long QT Syndrome Type 2 (LQTS 2) and Type 3 (LQTS 3)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Mar 7, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Thryv TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2) and Long QT Syndrome Type 3 (LQTS 3). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions this study aims to answer are: Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)? What side effects or medical problems occur when participants take THRV-1268? Which dose of THRV-1268 works best and is safest? Participants will: Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B - cohort 1) Have clinic visits and tests to monitor safety and changes in their heart rhythm May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2 and LQTS 3.

Conditions

  • Long QT Syndrome (LQTS) 2

Interventions

  • baseline lead-inOther

    Participants will undergo a 3 weeks run-in baseline

  • THRV-1268Drug

    THRV-1268 50 mg bid (total daily 100 mg) for 6 weeks

  • THRV-1268Drug

    THRV-1268 100 mg bid (total daily 200 mg) for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To evaluate the effect of oral THRV-1268 on QTcF interval by AUC method in participants with LQTS 2Time frame: Day 42 and Day 84
  2. Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])Time frame: up to 52 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research and Innovation Institute

    Scottsdale, Arizona · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • University of Illinois Chicago

    Chicago, Illinois · Recruiting

  • Heart Center Clinical Research Program | MGH

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Arbor, Michigan · Not yet recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • NYU Langone Health

    New York, New York · Not yet recruiting

  • Wilmington Health

    Wilmington, North Carolina · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.